Home > Pharmacy > Analytical chemistry > Volume-7 > Issue-6 > A Review of Telmisartan Angiotensin II Receptor Blocker: Treatment of Hypertension

A Review of Telmisartan Angiotensin II Receptor Blocker: Treatment of Hypertension

Call for Papers

Volume-8 | Issue-6

Last date : 27-Dec-2024

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area


A Review of Telmisartan Angiotensin II Receptor Blocker: Treatment of Hypertension


Tejaswini Kande | Mr. Laukik Raskar | Mr. Bharat Rathod | Srushti Rajpurohit | Shreya Salunke | Ms. Shubhangi Karkhile



Tejaswini Kande | Mr. Laukik Raskar | Mr. Bharat Rathod | Srushti Rajpurohit | Shreya Salunke | Ms. Shubhangi Karkhile "A Review of Telmisartan Angiotensin II Receptor Blocker: Treatment of Hypertension" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-6, December 2023, pp.393-401, URL: https://www.ijtsrd.com/papers/ijtsrd61199.pdf

Telmisartan, a long-acting antihypertensive agent is essential to achieve blood pressure control in the early morning due to its terminal elimination half-life of 24hrs and has a large volume of distribution. According to CBS classification it belongs to class II i.e. low solubility and high permeability. High volume of distribution coupled with high lipophilicity is the unique feature of angiotensin II receptor blocker, it offers the clinical advantage of good tissue penetration. It particularly blocks the angiotensin II receptor without blocking other receptors which are involved in cardiovascular regulation. According to recent data telmisartan 80mg controls early morning blood pressure more effectively than ramipril 5-10mg and has greater effect over cardiovascular risk. It is also more effective than losartan and in addition, angiotensin II blocker provides superior blood pressure control after a missed dose compared with valsartan 80mg.

Angiotensin II Blocker, Antihypertensive, Telmisartan, Cardiovascular Disease, Blood Pressure


IJTSRD61199
Volume-7 | Issue-6, December 2023
393-401
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin